{"filings":[{"id":746836,"accession_number":"0001493152-26-026364","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2026-05-29T20:13:38+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Enveric shareholders approve reverse stock split, reject increase in authorized shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split (1:5 to 1:15) approved: 793,344 for, 190,175 against, 8,309 abstentions.","Authorized share increase to 5B shares rejected: 427,158 for, 555,147 against, 9,523 abstentions.","Six director nominees elected: Michael Webb, George Kegler, Frank Pasqualone, Marcus Schabacker, Joseph Tucker, Sheila DeWitt.","Say-on-pay advisory vote passed: 569,552 for, 26,884 against, 5,297 abstentions.","Ratification of CBIZ CPAs as auditor passed: 960,728 for, 19,347 against, 11,753 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452720,"accession_number":"0001493152-26-023345","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2026-05-15T12:00:31+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enveric Biosciences Q1 net loss narrows to $1.6M; cash position improved to $10.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.6M ($1.08 loss per share) vs $2.2M ($14.58) in Q1 2025; cash $4.9M at March 31.","Raised gross $2.8M in Q1; subsequent $1.5M from warrant exercises and $5M upfront from $13.9M private placement.","As of May 15, cash balance approx $10.3M; expects to fund EB-003 activities into Q1 2027.","Advancing EB-003 toward IND; new preclinical data including PTSD model with rapid fear response reduction.","AbbVie withdrew PGR petition against Enveric patent covering bretisilocin; strengthens IP portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99495,"accession_number":"0001493152-26-020410","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Enveric corrects proxy error: reverse split ratio range is 1-for-5 to 1-for-15, not 1-for-50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected reverse split range from erroneously stated 1-for-50 to correct 1-for-15 in proxy statement.","Error appeared on proxy card and notice of internet availability; other proposal text was correct.","Meeting details (May 28, 2026, virtual, all proposals) remain unchanged; supplemental filing made April 30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99494,"accession_number":"0001493152-26-017960","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Enveric closes $5M private placement of shares and warrants with potential $8.9M additional proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$5M from sale of 2.22M shares/pre-funded warrants; potential $8.9M more if warrants exercised.","Warrants have exercise price of $2.00; Series I expire in 5 yrs, Series J in 18 months post-registration effective date.","H.C. Wainwright acted as placement agent, receiving 7% cash fee, 1% mgmt fee, and place agent warrants.","Proceeds to be used for product development, working capital, and general corporate purposes.","Offering closed on April 17, 2026 at $2.25 per share/warrant unit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115542,"accession_number":"0001493152-26-013290","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enveric Biosciences reports Q4 2025 net loss of $4.0M, cash $4.7M, advances EB-003 towards IND","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.0M in Q4 2025 ($6.12 per share) vs $3.2M loss ($58.06 per share) in Q4 2024; per-share impacted by 1:12 reverse split.","Cash $4.7M at Dec 31; raised $12.2M in gross proceeds during FY 2025; subsequently raised $1.5M (Jan 2026) and $1.45M (Feb 2026).","EB-003 showed positive preclinical results in chronic depression and PTSD models; preparing IND submission to FDA for first-in-human trial.","PGR petition by Gilgamesh/AbbVie against Enveric patent withdrawn; patent covers bretisilocin (GM-2505) acquired by AbbVie for $1.2B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115541,"accession_number":"0001493152-26-005606","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Enveric Biosciences registers additional $1.346M in shares under ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to register additional $1,346,000 of common stock under ATM agreement dated April 9, 2025.","Prior to filing, $1,853,878.34 in common stock had been sold under the same ATM agreement.","ATM agreement is with H.C. Wainwright & Co., LLC as sales agent.","Additional shares will be issued under same terms as existing at-the-market offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115540,"accession_number":"0001493152-26-004055","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Enveric Biosciences raises ~$1.5M in registered direct offering with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 328,802 shares at $4.41 per share in a registered direct offering, gross proceeds ~$1.5M.","Concurrent private placement: Series G and H warrants to buy up to 328,802 shares each at $4.16.","Series G warrants expire 5 years after resale registration effective date; Series H expire 18 months after.","Net proceeds ~$1.25M for product development, working capital, general corporate purposes.","H.C. Wainwright acted as placement agent; fees include 7% cash and placement agent warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115539,"accession_number":"0001493152-26-001151","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enveric Biosciences releases investor presentation; no key figures disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation furnished on Jan 9, 2026, for use with investors, analysts, and partners.","Presentation available on company website at enveric.com/investors/events.","No specific financial or operational figures were included in the exhibit text within the filing.","Confidence low due to absence of substantive data in the provided exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131975,"accession_number":"0001493152-25-027541","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Enveric Biosciences raises $3.1M via warrant exercise inducement at $7.05 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.1M from cash exercise of 426,390 existing warrants at reduced price of $7.05/sh.","Issued new Series E warrants (5-yr term) and Series F warrants (18-mo term) for up to 426,390 shares each at $7.05.","H.C. Wainwright served as placement agent; fees of 7.0% of gross proceeds plus placement agent warrants.","Net proceeds allocated to product development, working capital, and general corporate purposes.","Company to file resale registration statement for new warrant shares within 10 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131974,"accession_number":"0001493152-25-027196","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Enveric shareholders approve 50x increase in authorized shares and reverse split authority","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved increase in authorized common shares from 100M to 5B (50x) at board discretion.","Authorized reverse stock split at ratio between 1:5 and 1:15, with board to set exact ratio.","Issuance proposal to issue shares underlying warrants for Nasdaq Rule 5635 compliance passed.","Adjournment proposal rendered moot as quorum was achieved; all three proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131973,"accession_number":"0001493152-25-023444","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Enveric regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Nov 12, 2025 confirming compliance with Listing Rule 5550(a)(2).","Minimum bid price deficiency now considered closed by Nasdaq.","No further action required; company remains listed on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131972,"accession_number":"0001493152-25-023441","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enveric Biosciences Q3 net loss $3.4M, cash $3.8M; EB-003 advances toward IND 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.4M ($10.81 per share) in Q3 2025 vs $2.1M ($43.10) in Q3 2024; cash $3.8M as of Sept 30, 2025.","Lead candidate EB-003: completed pre-IND dose range studies, positive PTSD data, FDA pre-IND response; IND planned 2026.","Hired Fish & Richardson to defend U.S. Patent 12,138,276 against Gilgamesh PGR; patent covers Bretisilocin (AbbVie, $1.2B).","Completed reverse stock split 1:12 on Oct 28, 2025 after Nasdaq bid price deficiency delisting determination.","Gross proceeds of ~$2.2M from warrant exercise; $7.9M net raised in first nine months of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-35.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131971,"accession_number":"0001493152-25-019095","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["3.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Enveric Biosciences announces 1-for-12 reverse stock split to address Nasdaq bid-price deficiency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 8:00 a.m. ET on October 28, 2025; shares outstanding to drop from 6,219,568 to ~518,297.","Nasdaq notified company on Oct 22 of bid-price non-compliance (closing price <$1 for 30 days); no grace period due to prior reverse split.","Company received $2.2M gross from warrant exercises in September to raise stockholders' equity above $2.5M minimum.","Company intends to request a hearing to appeal delisting; no assurance of continued listing.","Warrants issued in the inducement become exercisable only after stockholder approval per Nasdaq Rule 5635(d)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148551,"accession_number":"0001493152-25-014073","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Enveric raises $2.2M in warrant exercise inducement; issues new Series C/D warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Holders exercised 1,212,499 Series A and 1,212,499 Series B warrants at reduced price of $0.915/share.","Gross proceeds ~$2.2M; H.C. Wainwright acted as placement agent (7% fee).","Company issued new unregistered Series C (2,424,998 shares, 5-yr term) and Series D (2,424,998 shares, 18-mo term) warrants at $0.915.","New warrants exercisable only after stockholder approval; proceeds for working capital and product development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148550,"accession_number":"0001641172-25-026143","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Enveric Biosciences moves HQ to Cambridge, MA; advances EB-003 toward IND in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Sept 2, 2025, principal executive offices changed to 245 First Street, 18th Floor, Cambridge, MA 02142.","Relocation aims to leverage Boston biotech hub for talent, collaboration, and capital access.","Lead candidate EB-003 (dual 5-HT2A/5-HT1B agonist) progressing toward IND; first-in-human trial anticipated in 2026.","EB-003 designed to provide neuroplastogenic benefits without hallucinatory effects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148549,"accession_number":"0001641172-25-026054","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enveric Biosciences files 8-K for investor presentation; no specific facts in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Management will release a Q3 2025 investor presentation on the company's website on or about Aug 29, 2025.","Presentation may be used with investors, analysts, lenders, and business partners.","No financial or operational details from the presentation are included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148548,"accession_number":"0001641172-25-026040","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Enveric Biosciences receives Nasdaq deficiency notice for failing minimum equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Enveric on Aug 26, 2025 that stockholders' equity of $2.18M as of June 30, 2025 is below $2.5M minimum.","Company has until Oct 10, 2025 to submit a plan to regain compliance; Nasdaq may grant a 180-day extension if plan is accepted.","If plan is rejected, Company may appeal to a Nasdaq Hearings Panel.","Company intends to submit a compliance plan and consider available options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148547,"accession_number":"0001641172-25-023724","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enveric Biosciences Q2 net loss $2.5M; EB-003 dual mechanism disclosed, IND on track for early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.5M ($0.97/shr) vs $1.9M ($3.72/shr) in Q2 2024; cash $2.8M at June 30.","Raised $4.9M net proceeds in first half 2025 via financing tools.","EB-003 reveals dual agonism at 5-HT2A (partial) and 5-HT1B receptors, a novel class.","IND submission for EB-003 expected early 2026; preclinical models show PTSD and depression efficacy.","Expanded IP portfolio: new patent filed, allowance for mescaline-derivative and tryptamine patents."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167385,"accession_number":"0001641172-25-013466","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Enveric stockholders approve conditional reverse stock split to avoid Nasdaq delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders authorized board to implement reverse stock split between 1:5 and 1:50 if Nasdaq issues bid price delisting determination before Jan 28, 2026.","Reverse stock split proposal passed with 881,471 votes for, 301,346 against, 23,681 abstentions.","All six director nominees elected; Michael D. Webb received 175,763 votes for, 155,118 withheld (875,617 broker non-votes).","Say-on-pay proposal passed with 253,560 votes for, 75,850 against, 1,471 abstentions.","Auditor ratification of CBIZ CPAs P.C. passed with 1,082,606 votes for, 115,857 against, 8,035 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167384,"accession_number":"0001641172-25-010275","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enveric Biosciences Q1 net loss narrows to $2.2M; progresses EB-003 IND timeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.2M in Q1 2025 vs $2.5M in Q1 2024; diluted loss per share $1.22 vs $9.21.","Cash and equivalents $4.3M at March 31, 2025, after closing $5M public offering.","New U.S. patent for EVM401 Series (mescaline derivatives) and EB-003 IP expanded.","Signed two licensing agreements for cannabinoid-COX-2 conjugates with Restoration Biologics.","Targeting FDA IND submission for EB-003 by end of Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167383,"accession_number":"0001641172-25-004320","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Enveric Biosciences dismisses Marcum LLP, engages CBIZ CPAs as new auditor effective April 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP dismissed as independent auditor; CBIZ CPAs P.C. engaged effective April 14, 2025 for FY 2025.","Marcum's reports for FY 2024 and 2023 contained no adverse opinion, except a going concern paragraph for FY 2024.","No disagreements or reportable events between Enveric and Marcum during the relevant periods.","Material weaknesses in internal controls over financial reporting continue, as previously disclosed.","Change follows CBIZ CPAs' acquisition of Marcum's attest business on November 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184699,"accession_number":"0001641172-25-001486","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enveric Biosciences Q4 2024 net loss $3.2M, cash $2.2M; out-licenses up to $144M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.2M for Q4 2024; diluted EPS loss $4.83; cash-on-hand $2.2M.","Out-licensing deals with Aries ($61M milestones), MycoMedica ($62M), Restoration Biologics ($82M).","Lead candidate EB-003 confirmed oral bioavailability and brain exposure; pre-IND activities ongoing.","Closed $5M public offering in 2024 to fund development."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184698,"accession_number":"0001493152-25-009336","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Enveric Biosciences regains Nasdaq bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice from Nasdaq on March 4, 2025 that it complied with Listing Rule 5550(a)(2).","Compliance resolves potential delisting risk due to low stock price.","Company's common stock continues trading on Nasdaq under symbol ENVB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184697,"accession_number":"0001493152-25-008281","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enveric Biosciences files 8-K to announce investor presentation; no specifics provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing reports availability of an investor presentation on company website as of Feb 26, 2025.","No financial results, guidance, or operational updates are disclosed in the filing.","Presentation may be used in meetings with investors, analysts, and other stakeholders.","Exhibit 99.1 is furnished but not summarized; specific content cannot be extracted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184696,"accession_number":"0001493152-25-004715","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Enveric Biosciences closes ~$5M public offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5M, net ~$4.3M from sale of 1.67M shares/pre-funded, Series A & B warrants at $3.00/unit.","Series A warrants (5-yr, $3.00 strike) and Series B warrants (18-mo, $3.00 strike) are exercisable immediately.","Proceeds earmarked for EB-003 development, working capital, and general corporate purposes.","H.C. Wainwright acted as placement agent, receiving 7% cash fee plus warrants to purchase 116,666 shares at $3.75.","Offering closed on February 3, 2025, with pre-funded warrants exercisable at $0.0001 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184693,"accession_number":"0001493152-25-003676","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K/A","filed_at":"2025-01-27T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Enveric corrects reverse stock split effective date to January 29, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of 1-for-15 will begin trading on Nasdaq Capital Market on January 29, 2025 (previously January 27).","Post-split CUSIP number: 29405E 406; trading symbol remains ENVB.","Amendment filed solely to correct the effective date; original split approved by board and stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184695,"accession_number":"0001493152-25-003091","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Enveric Biosciences announces 1-for-15 reverse stock split effective Jan 27, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse split at a special meeting on Jan 17, 2025; ratio range 1:10 to 1:100.","Board set ratio at 1-for-15; outstanding shares to reduce from ~10.4M to ~692,580.","No fractional shares; rounding up to next whole number; authorized shares remain 100M.","Trading symbol ENVB unchanged; new CUSIP 29405E 406; adjusted trading begins Jan 27."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184694,"accession_number":"0001493152-25-000247","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enveric Biosciences furnishes Q1 2025 investor presentation; content not detailed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation posted on company website on January 3, 2025.","No specific financial or operational updates provided in the filing text.","Investor materials available at https://www.enveric.com/investors/events/."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201274,"accession_number":"0001493152-24-047420","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Enveric Biosciences receives Nasdaq delisting notice on Nov 20 for bid price failure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Enveric on Nov 20, 2024, that it failed to meet the $1.00 minimum bid price requirement by the Nov 12 compliance deadline.","Company not eligible for a second 180-day extension due to insufficient stockholders' equity (below $5M initial listing requirement).","Enveric intends to appeal and request a hearing before the Nasdaq Listing Qualifications Panel.","Appeal stays delisting and trading suspension pending Panel decision; no guarantee of favorable outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201273,"accession_number":"0001493152-24-045840","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enveric Biosciences Q3 net loss narrows to $2.1M; advances EB-003","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.1M ($0.24/share) vs $2.8M ($1.30/share) a year ago; cash $3.1M.","Lead candidate EB-003 shows oral bioavailability and brain exposure; IND filing expected H2 2025.","Out-licensed radiation dermatitis product to Aries Science & Technology and EB-002 to MycoMedica.","Expanded patent estate with five new US patents for EVM301 portfolio."],"consensus_eps_estimate":-95.472,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201272,"accession_number":"0001493152-24-044572","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Enveric out-licenses EB-002 to MycoMedica for up to $62M milestones plus royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive global license for EB-002 (EVM201) to treat neuropsychiatric disorders.","Enveric receives modest upfront payments; eligible for up to $62M in development/sales milestones.","Tiered single-digit royalties on all future sales; MycoMedica has buyout options.","Enveric will focus resources on lead candidate EB-003, targeting IND filing in 2025.","MycoMedica assumes all future preclinical, clinical, and commercial development costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217300,"accession_number":"0001493152-24-033501","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enveric Biosciences files 8-K to announce investor presentation; no specific financial details provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing under Item 7.01 furnishes investor presentation (Exhibit 99.1) released on website on August 22, 2024 at 8:00 AM ET.","Presentation intended for use with investors, analysts, and business partners; no material new information disclosed in filing body.","No financial or operational metrics from the presentation are included in the filing; content of presentation not available for review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217299,"accession_number":"0001493152-24-031340","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enveric Biosciences reports Q2 2024 net loss of $1.7M; prioritizes EB-003 as lead candidate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.7M ($0.23/share) vs $6.4M loss in Q2 2023; cash on hand $3.5M.","Prioritized EB-003, a non-hallucinogenic neuroplastogenic molecule, as lead development candidate.","Preclinical data confirms oral bioavailability and brain exposure of EB-003; IND filing expected Q3 2025.","Signed licensing agreement with Aries Science & Technology for radiation dermatitis product; non-binding term sheets for joint disease and cancer treatments."],"consensus_eps_estimate":-100.98,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217298,"accession_number":"0001493152-24-027235","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Enveric licenses radiation dermatitis product to Aries; eligible for up to $61M in milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Akos (Enveric sub) grants Aries exclusive worldwide license for patented radiation dermatitis topical.","Enveric eligible for up to $61M in aggregate milestone payments plus tiered royalties of 2.5%-10%.","Market opportunity ~$400M annually; affects ~2M cancer patients per year.","Aries to lead clinical development and commercialization; Enveric to focus on neuropsychiatric.","Aries nominates Hari Harikumar as chairman-elect of subsidiary formed for this product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237110,"accession_number":"0001493152-24-021787","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Enveric Biosciences shareholders elect all six director nominees and approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected; Michael D. Webb received 767,013 for, 107,751 withheld.","Say-on-pay proposal approved (711,513 for, 116,232 against); advisory frequency set to one year (774,619 votes).","Ratification of Marcum LLP as auditor for FY2024 approved (2,485,258 for, 170,212 against).","Approx. 2.8M shares (38.75% of outstanding) represented, establishing quorum at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237109,"accession_number":"0001493152-24-021096","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Enveric Biosciences regains Nasdaq equity compliance; bid price deficiency remains","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 21, 2024 confirming compliance with minimum stockholders' equity requirement.","Stockholders' equity as of March 31, 2024 was $6,481,856.","Minimum bid price deficiency under Nasdaq Rule 5550(a)(2) remains outstanding.","Company intends to monitor bid price and consider available options to resolve the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237108,"accession_number":"0001493152-24-020489","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Enveric Biosciences receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price below $1.00 for 30 consecutive business days as of May 16, 2024.","Company has 180 days, until November 12, 2024, to regain compliance by closing at or above $1.00 for 10 consecutive days.","If not compliant by deadline, may be eligible for additional 180 days if other listing standards met.","Company considering available options, including potential reverse stock split, to cure deficiency.","Failure to regain compliance could result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237107,"accession_number":"0001493152-24-019362","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enveric Biosciences reports Q1 net loss of $2.46M, advances EB-003, signs seven non-binding term sheets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.46M ($0.61 per diluted share) vs $4.80M ($2.31) in Q1 2023; cash $6.36M.","Seven non-binding term sheets with four partners could yield up to $410M milestones plus future royalties.","Lead asset EB-003 advancing toward IND filing and Phase 1 trial.","Raised $4.5M from warrant exercises in Q1.","Drug discovery platform generated >1,000 proprietary candidates across seven molecule classes."],"consensus_eps_estimate":-142.29,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237106,"accession_number":"0001493152-24-017748","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Enveric issues 458K shares at $0.94 to waive equity line restriction; no proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 458,000 shares to institutional investors at $0.94 per share in registered direct offering.","Offering is to permanently waive variable rate transaction limitation from December 2023 Inducement Letters.","Company will not receive any net proceeds; waiver enables use of existing equity line of credit.","Company restricted from issuing additional shares for 30 days or until 15 million shares trade."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254692,"accession_number":"0001493152-24-011774","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Enveric sets May 28, 2024 Annual Meeting; stockholder proposal deadline April 8, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting scheduled for May 28, 2024, more than 30 days after 2023 meeting held Nov 2, 2023.","Stockholder proposals for director nominations must be received by April 8, 2024 at 5:00 PM ET.","Proposals must comply with Enveric's bylaws and SEC rules to be eligible for proxy inclusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254691,"accession_number":"0001493152-24-011235","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enveric Biosciences reports Q4 2023 net loss of $3.44M; selects EB-003, signs out-licensing term sheets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.44M ($1.46 per share) vs $8.80M ($4.89 per share) in Q4 2022.","Selected EB-003 as lead neuroplastogen candidate for depression/anxiety without hallucinations.","Signed non-binding term sheets to out-license three compound classes (up to $200M milestones) and cannabinoid conjugates (up to $61M).","Completed warrant inducement exercises raising ~$4.5M gross proceeds.","Advanced IND-enabling studies for EB-002 including toxicology and safety pharmacology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254690,"accession_number":"0001493152-24-010419","cik":890821,"company_name":"Enveric Biosciences, Inc.","ticker":"ENVB","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enveric signs non-binding term sheets for out-licensing joint disease compounds; up to $82M in milestones","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Two non-binding term sheets with undisclosed biotech to out-license cannabinoid-COX-2 conjugates for joint disease (osteoarthritis, rheumatoid arthritis).","Pharma license potential milestones up to ~$61M; non-pharma up to ~$21M; combined up to ~$82M.","Royalty rates: pharma 2.5%-10%, non-pharma 0.25%-7% on future sales; licensee funds all development.","CEO Joseph Tucker highlights second company to license Enveric assets; definitive agreements remain to be negotiated.","Enveric focuses on neuroplastogenic therapeutics; out-licensing diversifies revenue from its asset portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7879232.412556054,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}